2. Search Result
Search Result
Results for "

mice sepsis

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

5

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112288
    C188-9
    Maximum Cited Publications
    32 Publications Verification

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
    C188-9
  • HY-13687
    IKK 16
    30+ Cited Publications

    		 IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
    IKK 16
  • HY-N6871
    Abietic acid
    3 Publications Verification

    		 Bacterial IKK Ferroptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
    Abietic acid
  • HY-161834
    RG100204
    1 Publications Verification

    		 Pyroptosis Aquaporin NOD-like Receptor (NLR) p38 MAPK Infection Metabolic Disease Inflammation/Immunology
    RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
    RG100204
  • HY-N2393
    Kukoamine B
    1 Publications Verification

    		 Apoptosis MMP MAPKAPK2 (MK2) p38 MAPK PI3K Akt Reactive Oxygen Species (ROS) DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis .
    Kukoamine B
  • HY-N1990
    Gypenoside XLIX
    2 Publications Verification

    		 PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .
    Gypenoside XLIX
  • HY-103017A
    JH-X-119-01
    5+ Cited Publications

    		 IRAK Infection Inflammation/Immunology Cancer
    JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .
    JH-X-119-01
  • HY-18711A
    SCR-1481B1

    Metatinib anhydrous; c-Met inhibitor 2

    		 Pyroptosis Interleukin Related c-Met/HGFR VEGFR Cancer
    SCR-1481B1 (Metatinib anhydrous; c-Met inhibitor 2) is an inhibitor of the N-terminal fragment of Gasdermin D (GSDMD), with an IC50 of 1.04 μM and a Ka of 0.42 μM in mice. SCR-1481B1 effectively blocks GSDMD-NT oligomerization and pore formation, inhibits GSDMD-mediated pyroptosis (Pyroptosis), preserves mitochondrial integrity, and reduces proinflammatory cytokine secretion. SCR-1481B1 also inhibits angiogenesis, exerts GSDMD-independent antitumor effects, and enhances the infiltration of antitumor immune cells. SCR-1481B1 is also an inhibitor targeting to c-MET and VEGFR2, can be used in studies related to melanoma and sepsis .
    SCR-1481B1
  • HY-108882C
    DNase I (filtered)

    		DNA/RNA Synthesis Inflammation/Immunology
    DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune reactions. Decreased DNase I activity may be associated with the occurrence and development of systemic lupus erythematosus (SLE). DNase I (filtered) is filtered through a 0.22 μM membrane and is not tested for pyrogenicity .
    DNase I (filtered)
  • HY-W011522
    Taurolidine

    		Bacterial Apoptosis Antibiotic Autophagy Infection Cancer
    Taurolidine is a potent antimicrobial and anticancer agent. Taurolidine inhibits cell proliferation. Taurolidine induces apoptosis and autophagy. Taurolidine rescues mice from sepsis-associated lethality .
    Taurolidine
  • HY-103017
    JH-X-119-01 hydrochloride
    5+ Cited Publications

    		 IRAK Infection
    JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .
    JH-X-119-01 hydrochloride
  • HY-13687A
    IKK 16 hydrochloride
    30+ Cited Publications

    		 IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .
    IKK 16 hydrochloride
  • HY-B1206
    Neostigmine (methyl sulfate)
    1 Publications Verification

    		 Cholinesterase (ChE) Infection Neurological Disease
    Neostigmine methyl sulfate is an AchE inhibitor. Neostigmine methyl sulfate increases endogenous acetylcholine levels, mediates antinociceptive effects, and alleviates heat-induced pain. Neostigmine methyl sulfate can be used in studies related to postoperative pain and sepsis .
    Neostigmine (methyl sulfate)
  • HY-177204
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW

    		Ferroptosis Apoptosis Glutathione Peroxidase Cardiovascular Disease
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions .
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW
  • HY-W011522R
    Taurolidine (Standard)

    		Reference Standards Bacterial Apoptosis Antibiotic Autophagy Infection Cancer
    Taurolidine (Standard) is the analytical standard of Taurolidine. This product is intended for research and analytical applications. Taurolidine is a potent antimicrobial and anticancer agent. Taurolidine inhibits cell proliferation. Taurolidine induces apoptosis and autophagy. Taurolidine rescues mice from sepsis-associated lethality[1][2].
    Taurolidine (Standard)
  • HY-P4846
    Ac-Pro-Gly-Pro-OH
    2 Publications Verification

    		 CXCR Apoptosis IFNAR TNF Receptor Interleukin Related Infection Inflammation/Immunology
    Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer .
    Ac-Pro-Gly-Pro-OH
  • HY-N6893
    Ergolide
    3 Publications Verification

    		 NF-κB NOD-like Receptor (NLR) Apoptosis Autophagy Neurological Disease Cancer
    Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE2) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia .
    Ergolide
  • HY-N0469R
    L-Lysine (Standard)

    		Reference Standards Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)
  • HY-164102
    TNF-α-IN-18

    		TNF Receptor NF-κB Inflammation/Immunology
    TNF-α-IN-18 (Compound 61) is an inhibitor for TNF-α (IC50 of 1.8 μM), that inhibits TNF signaling pathway through block of NF-kB migration from cytoplasm to nucleus. TNF-α-IN-18 exhibits slight cytotoxicity to mouse fibroblast LM cell, with a CC50 >50 μM. TNF-α-IN-18 ameliorates the TNF- or Lipopolysaccharide (HY-D1056)-induced sepsis in mouse models. TNF-α-IN-18 protects mice from rheumatoid arthritis .
    TNF-α-IN-18
  • HY-12124
    BBS-4

    		NO Synthase Cardiovascular Disease
    BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC50 of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis .
    BBS-4
  • HY-103639A
    M62812

    		Toll-like Receptor (TLR) Infection
    M62812 is a toll-like receptor 4 (TLR4) signaling inhibitor. M62812 inhibits endothelial and leukocyte activation and prevents lethal septic shock in mice. M62812 can reduces LPS-induced coagulation and inflammatory responses. M62812 can be used for the research of sepsis .
    M62812
  • HY-174383
    PDE3/4-IN-2

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE3/4-IN-2 is a dual PDE3A and PDE4B1 inhibitor, with an IC50 of 0.13 nM against PDE3A and 50 nM against PDE4B1. PDE3/4-IN-2 exhibits higher systemic exposure and longer retention time in lung tissues in ICR mice. PDE3/4-IN-2 can be used in research on respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as autoimmune inflammation-related studies .
    PDE3/4-IN-2
  • HY-13687R
    IKK 16 (Standard)

    		IKK LRRK2 Reference Standards P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related Inflammation/Immunology
    IKK 16 (Standard) is the analytical standard of IKK 16. This product is intended for research and analytical applications. IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
    IKK 16 (Standard)
  • HY-161471
    DCLK1-IN-5

    		Ser/Thr Protease Inflammation/Immunology
    DCLK1-IN-5 (Compound a24) is a DCLK1 inhibitor (IC50: 179.7 nM). DCLK1-IN-5 inhibits lipopolysaccharide (HY-D1056)-induced inflammation via inhibiting DCLK1-mediated IKKβ phosphorylation. DCLK1-IN-5 protects mice against inflammation-induced lung injury and sepsis .
    DCLK1-IN-5
  • HY-103639
    M62812 free base

    		Toll-like Receptor (TLR) Inflammation/Immunology
    M62812 (free base) is a toll-like receptor 4 (TLR4) signal transduction inhibitor. M62812 can suppress endothelial cell and leukocyte activation and prevents lethal septic shock in mice. M62812 can be used for the research of sepsis .
    M62812 free base
  • HY-W744578
    Taurolidine-d6

    		Isotope-Labeled Compounds Apoptosis Bacterial Autophagy Antibiotic Cancer
    Taurolidine-d6 is the deuterium labeled Taurolidine (HY-W011522). Taurolidine is a potent antimicrobial and anticancer agent. Taurolidine inhibits cell proliferation. Taurolidine induces apoptosis and autophagy. Taurolidine rescues mice from sepsis-associated lethality .
    Taurolidine-d6
  • HY-N2393A
    Kukoamine B mesylate

    		Apoptosis MMP MARK PI3K Akt ROS Kinase DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
    Kukoamine B mesylate
  • HY-N2393S
    Kukoamine B-d5 dihydrochloride

    		MMP Apoptosis MAPKAPK2 (MK2) p38 MAPK PI3K Akt ROS Kinase DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
    Kukoamine B-d5 dihydrochloride
  • HY-161059
    ZB-R-55

    		RIP kinase Necroptosis Infection Inflammation/Immunology
    ZB-R-55 is an orally active and selective dual-mode RIPK1 inhibitor with RIPK1 IC50 values of 5.7 nM. ZB-R-55 occupies both the allosteric and ATP binding sites of RIPK1. ZB-R-55 inhibits necroptosis in cancer cells. ZB-R-55 can be used for the research of systemic inflammatory response syndrome and sepsis .
    ZB-R-55
  • HY-184000
    SIRT5-IN-10

    		Sirtuin JAK STAT Interleukin Related Endocrinology
    SIRT5-IN-10 is a competitive SIRT5 inhibitor. SIRT5-IN-10 improves renal function and reduces histopathological damage in septic acute kidney injury (AKI) mice. SIRT5-IN-10 can be used for the research of sepsis-associated AKI .
    SIRT5-IN-10
  • HY-103017R
    JH-X-119-01 hydrochloride (Standard)

    		Reference Standards IRAK Infection
    JH-X-119-01 hydrochloride (Standard) is the analytical standard of JH-X-119-01 hydrochloride (HY-103017). This product is intended for research and analytical applications. JH-X-119-01 hydrochloride is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 hydrochloride ameliorates LPS-induced sepsis in mice .
    JH-X-119-01 hydrochloride (Standard)
  • HY-103639AR
    M62812 (Standard)

    		Reference Standards Toll-like Receptor (TLR) Infection
    M62812 (Standard) is the analytical standard of M62812 (HY-103639A). This product is intended for research and analytical applications. M62812 is a toll-like receptor 4 (TLR4) signaling inhibitor. M62812 inhibits endothelial and leukocyte activation and prevents lethal septic shock in mice. M62812 can reduces LPS-induced coagulation and inflammatory responses. M62812 can be used for the research of sepsis .
    M62812 (Standard)
  • HY-P11603
    SK56

    		Pyroptosis Inflammation/Immunology
    SK56 is a GSDMD-NT pore inhibitor. SK56 inhibits pyroptosis (Pyroptosis) and the release of pyroptosis-related cytokines in macrophages and human peripheral blood leukocytes. SK56 prevents extensive cell death in human alveolar organoids in an organoid-macrophage co-culture model. SK56 prevents death from infectious shock induced by LPS (HY-D1056) or cecal ligation and puncture in mice. SK56 can be used in studies related to sepsis .
    SK56
  • HY-184324
    Anti-inflammatory agent 116

    		NF-κB p38 MAPK Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor COX IKK ERK JNK Metabolic Disease
    Anti-inflammatory agent 116 is an anti-inflammatory agent. Anti-inflammatory agent 116 inhibits the abnormal activation of the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 116 binds to the p50 subunit and impairs the DNA-binding ability of the p65-p50 heterodimer. Anti-inflammatory agent 116 inhibits LPS-induced production of NO and MtROS, secretion of IL-1β and TNF-α, expression of iNOS and COX-2, phosphorylation of IKK, IκB, p65, p38, ERK and JNK, as well as nuclear translocation of p65. Anti-inflammatory agent 116 alleviates sepsis-associated acute liver injury in mice. Anti-inflammatory agent 116 can be used for the research of sepsis-associated acute liver injury .
    Anti-inflammatory agent 116
  • HY-107044
    DK 507k

    		Bacterial Topoisomerase Infection
    DK 507k is an orally active 8-methoxyquinolone Antibacterial agent. DK 507k targets DNA gyrase subunit A (GyrA) and modulates the function of GyrA. DK 507k inhibits the growth of various Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. DK 507k eliminates Penicillin-tolerant Streptococcus pneumoniae from the lungs of mice. DK 507k can be used in research related to sepsis and *Streptococcus pneumoniae* pneumonia .
    DK 507k
  • HY-181088
    PDE3/4-IN-4

    		Phosphodiesterase (PDE) Interleukin Related Metabolic Disease
    PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury .
    PDE3/4-IN-4
  • HY-103017AR
    JH-X-119-01 (Standard)

    		Reference Standards IRAK Infection Inflammation/Immunology Cancer
    JH-X-119-01 (Standard) is the analytical standard of JH-X-119-01 (HY-103017A). This product is intended for research and analytical applications. JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .
    JH-X-119-01 (Standard)
  • HY-179701
    NIK-IN-3

    		NF-κB TNF Receptor Interleukin Related CXCR Inflammation/Immunology
    NIK-IN-3 is a potent and orally active NF-κB-inducing kinase (NIK) inhibitor with an IC50 of 5.2 nM. NIK-IN-3 suppresses non-canonical NF-κB pathway activation and inhibits the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β and chemokine CXCL12. NIK-IN-3 shows significant anti-inflammatory effects in LPS (HY-D1056)-induced sepsis mice model and DSS (HY-116282)-induced colitis model. NIK-IN-3 can be used for the research of inflammation, such as colitis .
    NIK-IN-3
  • HY-183296
    NLRP3-IN-91

    		NOD-like Receptor (NLR) Interleukin Related Caspase Inflammation/Immunology
    NLRP3-IN-91 is a potent NLRP3 inflammasome inhibitor with a Kd of 558.4 nM. NLRP3-IN-91 directly targets the NLRP3 NACHT domain, blocks inflammasome assembly and activation, and exerts anti-inflammatory effects. NLRP3-IN-91 increases survival time in a murine model of LPS (HY-D1056)-induced sepsis. NLRP3-IN-91 can be used for the research of sepsis .
    NLRP3-IN-91
  • HY-114214
    CKD-712

    		Drug Derivative NF-κB MMP TNF Receptor Interleukin Related Cyclin G-associated Kinase (GAK) CDK PI3K Akt Inflammation/Immunology Cancer
    CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-κB pathway . CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-α, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway . CKD-712 blocks the activation and nuclear translocation of NF-κB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells . CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer .
    CKD-712
  • HY-P11791
    nNIF peptide

    		Endogenous Metabolite Infection
    nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis .
    nNIF peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: